Insights into Vestibular Migraine: Diagnostic Challenges, Differential Spectrum and Therapeutic Horizons
Marlon Cantillo-Martínez, Joan Lorente-Piera, Raquel Manrique‐Huarte, Margarita Sánchez del Río, Nicolás Pérez‐Fernández, Carlos Chico-Vila, David Moreno‐Ajona, Pablo Irimia
Abstract
Vestibular migraine (VM) commonly causes recurrent vertigo, but diagnosing and managing it can be difficult due to symptom overlap with other vestibular and headache disorders. This review provides a comprehensive update on VM, beginning with the diagnostic criteria established by the International Headache Society and the Bárány Society, who have increased awareness of this condition. While the pathophysiology is not yet completely understood, there is evidence of a complex interaction between the nociceptive and vestibular systems. Treatment approaches are primarily empirical and lack robust, high-quality evidence. Often, antihistamines and benzodiazepines are used for quick symptom relief, while the efficacy of triptans is still uncertain. Preventive measures include lifestyle changes, vestibular rehabilitation, oral migraine prophylactics, Botulinum toxin type A, and, more recently, CGRP-targeted therapies. Due to diagnostic uncertainties and the absence of standardised treatment protocols, further research-particularly randomised controlled trials-is crucial for establishing evidence-based guidelines.